This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, more promising evidence for the therapeutic potential of a neoantigen–based cancer vaccine used in the adjuvant setting is reported from the American Association for Cancer Research 2024 meeting. In addition, articles address a significant overall survival benefit with dostarlimab plus chemotherapy in advanced endometrial cancer, and a favorable overall survival trend with pembrolizumab plus chemotherapy for endometrial cancer.
No takes yet. Share an insight, caveat, or question.
Mary Beth Nierengarten (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: